Monograph Details
|
|
Cardiovascular System
> Edema
|
|
MAXZIDE-25mg |
| Manufacturer |
|
Bertek Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
K+-sparing + thiazide. |
| Generic Name |
|
Triamterene 37.5mg, hydrochlorothiazide 25mg; scored tabs. |
| Also |
|
• MAXZIDE
|
| Indications |
|
Edema. |
| Children |
|
Not recommended. |
| Adults |
|
Initially one Maxzide-25 tab/day. Usual dosage: 1–2 Maxzide-25 tabs or one Maxzide tab once daily. As a substitute for triamterene 50–100mg/day and hydrochlorothiazide 25–50mg/day in less bioavailable form, give one Maxzide-25 tab/day. |
| Contraindications |
|
Hyperkalemia. Renal impairment. Anuria. Sulfonamide allergy. Concomitant potassium or K+-sparing diuretics. |
| Precautions |
|
Diabetes. Acidosis predisposition. Electrolyte imbalance. Excessive diuresis. History of renal stones. Gout. Asthma. SLE. Surgery. Monitor electrolytes, renal function. Discontinue if serum potassium >5.5mEq/L or <3mEq/L. Hepatic impairment: monitor for hepatic coma, if confusion increases, discontinue for a few days. Elderly. Severely ill. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. Hyperkalemia more likely with ACE inhibitors. NSAIDs may cause renal failure. Hypokalemia with corticosteroids, ACTH, amphotericin B. Hypotension with CNS depressants. Potentiates other antihypertensives, nondepolarizing muscle relaxants. Antagonized by NSAIDs. Hyponatremia with sulfonylureas. Antagonizes folic acid. May block epinephrine. May interfere with parathyroid tests. |
| Adverse Reactions |
|
Drowsiness, insomnia, muscle cramps, weakness, headache, GI disturbances, dizziness, orthostatic hypotension, hyperuricemia, impotence, renal stones, tachycardia, dyspnea, dry mouth, depression, anxiety, urine discoloration, elevated liver enzymes. |
| How Supplied |
|
Tabs—100, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
